Equities

Dr Reddy's Laboratories Ltd

Dr Reddy's Laboratories Ltd

Actions
  • Price (EUR)68.50
  • Today's Change2.50 / 3.79%
  • Shares traded75.00
  • 1 Year change+26.85%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

  • Revenue in USD (TTM)3.25bn
  • Net income in USD625.97m
  • Incorporated1984
  • Employees25.86k
  • Location
    Dr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500034IndiaIND
  • Phone+91 4 049002900
  • Fax+91 4 049002999
  • Websitehttps://www.drreddys.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DRREDDY:NSI since
announced
Transaction
value
Menolabs LLCDeal completed11 Dec 202311 Dec 2023Deal completed8.39%3.00m
Data delayed at least 15 minutes, as of Apr 26 2024 11:26 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.